{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:26:40Z","timestamp":1792628800719,"version":"4.5.0"},"reference-count":14,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"\n Importance<\/jats:title>\n The microbiota-gut-brain axis is a promising target for novel treatments for mood disorders, such as probiotics. However, few clinical trials have been conducted, and further safety and efficacy data are needed to support this treatment approach.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To provide acceptability and tolerability data and estimates of intervention effect size for probiotics as adjunctive treatment for patients with major depressive disorder (MDD).<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n In this single-center, double-blind, placebo-controlled pilot randomized clinical trial, adults aged 18 to 55 years with MDD taking antidepressant medication but having an incomplete response were studied. A random sample was recruited from primary and secondary care services and general advertising in London, United Kingdom. Data were collected between September 2019 and May 2022 and analyzed between July and September 2022.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Multistrain probiotic (8 billion colony-forming units per day) or placebo daily for 8 weeks added to ongoing antidepressant medication.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The pilot outcomes of the trial were retention, acceptability, tolerability, and estimates of putative treatment effect on clinical symptoms (depression: Hamilton Depression Rating Scale [HAMD-17] and Inventory of Depressive Symptomatology [IDS] scores; anxiety: Hamilton Anxiety Rating Scale [HAMA] and General Anxiety Disorder [GAD-7] scores) to be used as indicators for a definitive trial.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 50 included participants, 49 received the intervention and were included in intent-to-treat analyses; of these, 39 (80%) were female, and the mean (SD) age was 31.7 (9.8) years. A total of 24 were randomized to probiotic and 25 to placebo. Attrition was 8% (1 in the probiotic group and 3 in the placebo group), adherence was 97.2%, and there were no serious adverse reactions. For the probiotic group, mean (SD) HAMD-17 scores at weeks 4 and 8 were 11.00 (5.13) and 8.83 (4.28), respectively; IDS, 30.17 (11.98) and 25.04 (11.68); HAMA, 11.71 (5.86) and 8.17 (4.68); and GAD-7, 7.78 (4.12) and 7.63 (4.77). For the placebo group, mean (SD) HAMD-17 scores at weeks 4 and 8 were 14.04 (3.70) and 11.09 (3.22), respectively; IDS, 33.82 (9.26) and 29.64 (9.31); HAMA, 14.70 (5.47) and 10.95 (4.48); and GAD-7, 10.91 (5.32) and 9.48 (5.18). Standardized effect sizes (SES) from linear mixed models demonstrated that the probiotic group attained greater improvements in depressive symptoms according to HAMD-17 scores (week 4: SES, 0.70; 95% CI, 0.01-0.98) and IDS Self Report scores (week 8: SES, 0.64; 95% CI, 0.03-0.87) as well as greater improvements in anxiety symptoms according to HAMA scores (week 4: SES, 0.67; 95% CI, 0-0.95; week 8: SES, 0.79; 95% CI, 0.06-1.05), but not GAD-7 scores (week 4: SES, 0.57; 95% CI, \u22120.01 to 0.82; week 8: SES, 0.32; 95% CI, \u22120.19 to 0.65), compared with the placebo group.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The acceptability, tolerability, and estimated effect sizes on key clinical outcomes are promising and encourage further investigation of probiotics as add-on treatment for people with MDD in a definitive efficacy trial.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT03893162<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2023.1817","type":"journal-article","created":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T11:01:18Z","timestamp":1686740478000},"page":"842","source":"Crossref","is-referenced-by-count":137,"title":["Acceptability, Tolerability, and Estimates of Putative Treatment Effects of Probiotics as Adjunctive Treatment in Patients With Depression"],"prefix":"10.1001","volume":"80","author":[{"given":"Viktoriya L.","family":"Nikolova","sequence":"first","affiliation":[{"name":"Centre for Affective Disorders, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London, London, United Kingdom"},{"name":"ADM Health & Wellness, ADM Protexin, Somerset, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Cleare","sequence":"additional","affiliation":[{"name":"Centre for Affective Disorders, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London, London, United Kingdom"},{"name":"National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King\u2019s College London, London, United Kingdom"},{"name":"South London and Maudsley NHS Foundation Trust, Bethlem Royal Hospital, Beckenham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan H.","family":"Young","sequence":"additional","affiliation":[{"name":"Centre for Affective Disorders, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London, London, United Kingdom"},{"name":"National Institute for Health Research Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King\u2019s College London, London, United Kingdom"},{"name":"South London and Maudsley NHS Foundation Trust, Bethlem Royal Hospital, Beckenham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Stone","sequence":"additional","affiliation":[{"name":"Centre for Affective Disorders, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London, London, United Kingdom"},{"name":"Brighton and Sussex Medical School, Brighton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"11","key":"ybr230004r1","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"4","key":"ybr230004r2","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3390\/jcm10040647","article-title":"Updated review and meta-analysis of probiotics for the treatment of clinical depression: adjunctive vs. stand-alone treatment.","volume":"10","author":"Nikolova","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"ybr230004r3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41398-022-01977-z","article-title":"Clinical, gut microbial and neural effects of a probiotic add-on therapy in depressed patients: a randomized controlled trial.","volume":"12","author":"Schaub","year":"2022","journal-title":"Transl Psychiatry"},{"issue":"1","key":"ybr230004r4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression.","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ybr230004r5","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.3389\/fnins.2019.01361","article-title":"Antidepressive mechanisms of probiotics and their therapeutic potential.","volume":"13","author":"Yong","year":"2020","journal-title":"Front Neurosci"},{"issue":"2","key":"ybr230004r6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/(ISSN)1557-0657","article-title":"The Inventory of Depressive Symptomatology (IDS): Clinician (IDS-C) and Self-Report (IDS-SR) ratings of depressive symptoms.","volume":"9","author":"Rush","year":"2000","journal-title":"Int J Methods Psychiatr Res"},{"issue":"1","key":"ybr230004r7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/papt.1959.32.issue-1","article-title":"The assessment of anxiety states by rating.","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br J Med Psychol"},{"issue":"10","key":"ybr230004r8","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7.","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch Intern Med"},{"issue":"3","key":"ybr230004r10","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1177\/0962280215588241","article-title":"Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable.","volume":"25","author":"Whitehead","year":"2016","journal-title":"Stat Methods Med Res"},{"issue":"3","key":"ybr230004r12","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1017\/S0033291700035558","article-title":"The Inventory of Depressive Symptomatology (IDS): psychometric properties.","volume":"26","author":"Rush","year":"1996","journal-title":"Psychol Med"},{"key":"ybr230004r13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.neubiorev.2019.03.023","article-title":"Prebiotics and probiotics for depression and anxiety: a systematic review and meta-analysis of controlled clinical trials.","volume":"102","author":"Liu","year":"2019","journal-title":"Neurosci Biobehav Rev"},{"issue":"7","key":"ybr230004r14","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1017\/S0033291704002612","article-title":"Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D.","volume":"34","author":"Fava","year":"2004","journal-title":"Psychol Med"},{"key":"ybr230004r9","volume-title":"ECDEU Assessment Manual for Psychopharmacology, Revised","author":"Guy","year":"1976"},{"key":"ybr230004r11","unstructured":"Research Design Service. Justify sample size for a feasibility study. Accessed October 7, 2022. https:\/\/www.rds-london.nihr.ac.uk\/resources\/justify-sample-size-for-a-feasibility-study\/"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2806011\/jamapsychiatry_nikolova_2023_br_230004_1690301869.99661.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T11:03:05Z","timestamp":1690974185000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2806011"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2023.1817","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,1]]}}}